LaingBuisson News
Former CEO and president of The Revenio Group, Timo Hildén, has been appointed chairman of the board of directors at Finnish medtech startup, Nukute.
Nukute develops high-tech tools for the diagnosis and testing of respiratory diseases and conditions, including the home sleep apnea testing (HSAT) product.
Alongside Hildén, Nukute appointed another two new members to the board: Tommi Mäkelä as the representative of the Pharmacy Pension Fund (Finland), and Frans Wuite, CEO of Kompassi. Johannes Gullichsen, Pekka Virtanen and Timo Laitinen continue as members.
“Nukute demonstrates well the high level of medical technology innovation found in Finland today. The next couple of years will be very interesting as Nukute begins its commercial growth both in Finland and abroad and as it receives more and more clinical interest and acceptance,” said Hildén.